CSF2 and neuroblastoma: Dinutuximab (ch14.18) is a chimeric monoclonal antibody approved by FDA in 2015 for the treatment of HR-NB, in combination with 13-cis-retinoic acid (RA), interleukin-2 (IL-2), and granulocyte-macrophage colony-stimulating factor (GM-CSF) [19].